Soluble transferrin receptor
| Soluble Transferrin Receptor | |
|---|---|
| Synonyms | N/A |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | N/A |
| Complications | N/A |
| Onset | N/A |
| Duration | N/A |
| Types | N/A |
| Causes | N/A |
| Risks | N/A |
| Diagnosis | N/A |
| Differential diagnosis | N/A |
| Prevention | N/A |
| Treatment | N/A |
| Medication | N/A |
| Prognosis | N/A |
| Frequency | N/A |
| Deaths | N/A |
The soluble transferrin receptor (sTfR) is a truncated form of the transferrin receptor that circulates in the blood. It is a valuable biomarker in the diagnosis and management of various conditions related to iron metabolism and erythropoiesis.
Structure and Function[edit]
The transferrin receptor is a membrane-bound protein that facilitates the uptake of iron into cells by binding to transferrin, the main iron transport protein in the blood. The receptor is composed of two subunits, each with a molecular weight of approximately 95 kDa. The soluble form of the transferrin receptor is generated by proteolytic cleavage of the extracellular domain of the membrane-bound receptor.
The sTfR retains the ability to bind transferrin, but it does not mediate iron uptake. Instead, it circulates in the plasma and reflects the total body mass of transferrin receptors, which is proportional to the body's iron requirements and erythropoietic activity.
Clinical Significance[edit]
The measurement of sTfR levels in the blood is useful in distinguishing between different types of anemia. It is particularly helpful in differentiating iron deficiency anemia from anemia of chronic disease.
Iron Deficiency Anemia[edit]
In iron deficiency anemia, the body's iron stores are depleted, leading to increased expression of transferrin receptors on cell surfaces to enhance iron uptake. Consequently, sTfR levels are elevated in iron deficiency anemia, reflecting the increased demand for iron.
Anemia of Chronic Disease[edit]
In contrast, anemia of chronic disease is characterized by normal or low sTfR levels. This is because the anemia is not due to iron deficiency but rather due to impaired iron utilization and sequestration of iron in macrophages, often associated with chronic inflammation or infection.
sTfR-Ferritin Index[edit]
The sTfR-ferritin index, calculated as the ratio of sTfR to ferritin, is a useful parameter for assessing iron status. A high sTfR-ferritin index suggests iron deficiency, while a low index is indicative of anemia of chronic disease.
Diagnostic Use[edit]
The sTfR assay is a valuable tool in the evaluation of erythropoietic activity. It is particularly useful in:
- Assessing iron status in patients with chronic kidney disease or heart failure, where traditional markers like ferritin may be affected by inflammation.
- Monitoring response to erythropoiesis-stimulating agents in patients undergoing treatment for anemia.
- Evaluating iron status in athletes, where increased erythropoietic activity may lead to elevated sTfR levels.
Limitations[edit]
While sTfR is a useful marker, it is not without limitations. Factors such as hemolysis, recent blood transfusions, and certain hematological disorders can affect sTfR levels. Additionally, the assay is not standardized across different laboratories, which can lead to variability in results.
Conclusion[edit]
The soluble transferrin receptor is a crucial biomarker in the assessment of iron status and erythropoietic activity. Its measurement provides valuable insights into the underlying causes of anemia and helps guide appropriate management strategies.
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian